With A Transformational Year Underway, Insmed Ramps Up

With a reliable source of revenue in Arikayce and two key pulmonary late-stage trials reading out, Insmed aims to keep its commercial momentum going.

Spaceship blueprints
'I feel like we're building a rocket that's about to take off.' • Source: Shutterstock

Will Lewis, CEO of New Jersey-based Insmed Incorporated, believes this year will be transformational for the company, not least because it has several parallel late-stage clinical programs reaching maturation.

“We’re stacking a lot of events on top of each other that are quite significant for the company,” Lewis told...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from C-Suite Speaks

Vigya test infogram

add a desc test

Bristol Myers Squibb ASPIREs For Access In LMICs

BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.

Crossject Tackles Needle Phobia In Emergency Settings

 

Patrick Alexandre, Crossject CEO, discusses crucial developments happening for Zeneo, a needle-free injector, functioning intramuscularly to administer medication in a tenth of a second

More from Leadership

In Vivo’s 2026 Rising Leaders

 
• By 

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

How To Decarbonize Pharma R&D

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.